ClinicalTrials.gg
CompletedNCT06208306AERIFY-4Updated Sep 18, 2026

A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD

A Phase 3 interventional study of Itepekimab (SAR440340) and Placebo in Chronic Obstructive Pulmonary Disease, sponsored by Sanofi. Completed at 223 sites in 32 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
669
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi — 7 open to participants now, 7 under way, 3 of them phase 3. Pulmonary Disease, Chronic Obstructive · Sanofi.

Enrollment
8th of 12
669 · median 937
Started
2024
the only one that year
Phase 3
8 of 15
3 open now
Registered
8th of 15
by date

Among the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, this one is the 8th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2024, is one of 8 in phase 3, and was the 8th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

7 of the 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pulmonary Disease, Chronic Obstructive by Sanofi, or all of them as a file.
02

Study summary

This is a parallel, double blind, Phase 3, 2-arm study that is designed to provide additional safety information, assess the durability of treatment response, and provide additional PK and immunogenicity assessments.

The primary purpose of this study is to evaluate safety and tolerability of both itepekimab SC Q2W or itepekimab SC Q4W in participants with COPD having completed the treatment period of the clinical studies EFC16750 or EFC16819. A secondary purpose of this study is to provide efficacy outcomes beyond the treatment period of the parent trials EFC16750 and EFC16819.

Study details include:

  • The study duration will be up to 72 weeks
  • The treatment duration will be up to 52 weeks
  • A follow-up period of 20 weeks will be conducted
  • The number of on-site visits will be 7 and the number of phone contacts will be 5
03

Conditions studied

  • Chronic Obstructive Pulmonary Disease
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Patients with who completed the treatment period in a previous itepekimab COPD Phase 3 clinical study (ie, EFC16750 or EFC16819) and for which an end-of-treatment (EOT) visit occurred no later than 3 days before the enrolment visit of this study.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of a during parent study, except a squamous or basal cell carcinoma of the skin
  • Any opportunistic infection during the parent study, such as tuberculosis (TB) or other infections whose nature or course may suggest an status
  • Anaphylactic reactions or systemic allergic reactions that are related to IMP and require treatment during the parent study
  • Any situation that led to a permanent premature IMP discontinuation in parent trials

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
669 participants (actual)

Study arms

  • Experimental
    Itepekimab Q2W

    Subcutaneous (SC) administration of Itepekimab every 2 weeks (Q2W) for up to 52 weeks

    Drug: Itepekimab (SAR440340)

  • Experimental
    Itepekimab Q4W

    SC administration of Itepekimab every 4 weeks (Q4W) for up to 52 weeks, with alternating SC administration of matching placebo at the 2-week interval between active IMP

    Drug: Itepekimab (SAR440340) · Drug: Placebo

Interventions

  • Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

    Also known as: REGN3500

  • DrugPlacebo

    Pharmaceutical form:solution for injection in pre-filled syringe Route of administration:subcutaneous

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent AEs, AESIs, SAEs, and AEs leading to permanent treatment discontinuation

    All AEs (serious or nonserious) will be collected from the signing of the informed consent form (ICF) until the end of study visit

    Time frame: Baseline up to Week 72

Secondary outcomes

  1. Functional itepekimab concentrations in serum

    Time frame: Baseline up to Week 52

  2. Incidence of treatment-emergent (TE) anti-drug antibody responses

    Time frame: Baseline up to Week 72

  3. Annualized rate of moderate-to-severe acute exacerbation of COPD (AECOPD)

    Time frame: Baseline up to Week 52

  4. Annualized rate of severe AECOPD

    Time frame: Baseline up to Week 52

  5. Time to first moderate-to-severe AECOPD

    Time frame: Baseline up to Week 52

  6. Time to first severe AECOPD

    Time frame: Baseline up to Week 52

  7. Change from baseline of the parent studies (EFC16750, EFC16819): Pre-BD and post-BD FEV1

    FEV1 is force expiratory volume in 1 second

    Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52

  8. Change from baseline of the parent studies (EFC16750, EFC16819): SGRQ total score and domain scores

    The St. George's Respiratory Questionnaire (SGRQ) is a 50-item questionnaire designed to measure and quantify health status in adult participants with chronic airflow limitation.

    Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52

  9. Change from baseline of the parent studies (EFC16750, EFC16819): EQ-5D-5L single index score

    The European Quality of Life 5 Dimensions 5 Level Version (EQ 5D 5L) is a standardized health-related quality-of-life (HRQoL) questionnaire which consists of a descriptive system and the EuroQol visual analog scale (EQ-VAS).

    Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52

  10. Change from baseline of the parent studies (EFC16750, EFC16819): EQ-VAS

    The EuroQol visual analog scale (EQ VAS) records the participant's self-rated health on a vertical VAS.

    Time frame: Baseline of the parent studies (EFC16750,EFC16819) up to Week 52

  11. Change from Week 0 for CASA-Q

    The cough and sputum assessment questionnaire (CASA-Q) was developed for use in COPD and chronic (non-obstructive) bronchitis patients.

    Time frame: Baseline up to Week 52

07

Study locations

223 sites
  • Chandler Clinical Research Trials- Site Number : 8401034
    Chandler, Arizona 85224, United States
  • Noble Clinical Research Site Number : 8401182
    Tucson, Arizona 85704, United States
  • Tucson Clinical Research Institute- Site Number : 8401431
    Tucson, Arizona 85712, United States
  • IMAX Clinical Trials- Site Number : 8401419
    La Palma, California 90623, United States
  • Antelope Valley Clinical Trials Site Number : 8401003
    Lancaster, California 93534, United States
  • Downtown L.A. Research Center- Site Number : 8401027
    Los Angeles, California 90017, United States
  • Allianz Research Institute CO Site Number : 8402061
    Aurora, Colorado 80014, United States
  • Alpine Clinical Research Center - Boulder - 47th Street- Site Number : 8401180
    Boulder, Colorado 80301, United States
  • Helix Biomedics- Site Number : 8402049
    Boynton Beach, Florida 33435, United States
  • Beautiful Minds Clinical Research Center Site Number : 8401201
    Cutler Bay, Florida 33157, United States
  • Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8402031
    DeBary, Florida 32713, United States
  • Science Connections, LLC Site Number : 8402045
    Doral, Florida 33178, United States
  • Direct Helpers Research Center- Site Number : 8402065
    Hialeah, Florida 33012, United States
  • Premier Medical Associates Site Number : 8401388
    Lady Lake, Florida 32159, United States
  • Advanced Pulmonary Research Institute Site Number : 8402018
    Loxahatchee Groves, Florida 33470, United States
  • Finlay Medical Research- Site Number : 8402007
    Miami, Florida 33126, United States
  • Elite Clinical Research - Miami- Site Number : 8402009
    Miami, Florida 33144, United States
  • DL Research Solutions- Site Number : 8401033
    Miami, Florida 33155, United States
  • My Community Research Center Site Number : 8402060
    Miami, Florida 33155, United States
  • Phoenix Medical Research - Miami - 24th Street- Site Number : 8402019
    Miami, Florida 33165, United States
  • Research Institute of South Florida- Site Number : 8401006
    Miami, Florida 33173, United States
  • Reed Medical Research Site Number : 8401032
    Miami, Florida 33176, United States
  • High Quality Research Site Number : 8401406
    Miami, Florida 33184, United States
  • Deluxe Health Center Site Number : 8401188
    Miami Lakes, Florida 33014, United States
  • Renstar Medical Research - Ocala - Northeast 1st Avenue- Site Number : 8402015
    Ocala, Florida 34470, United States
  • Heuer M.D. Research- Site Number : 8402016
    Orlando, Florida 32819, United States
  • Florida Institute for Clinical Research Site Number : 8401013
    Orlando, Florida 32825, United States
  • Oviedo Medical Research Site Number : 8402026
    Oviedo, Florida 32765, United States
  • Innovation Medical Research Center - Palmetto Bay- Site Number : 8402067
    Palmetto Bay, Florida 33157, United States
  • Pines Care Research Center- Site Number : 8402056
    Pembroke Pines, Florida 33024, United States
  • Tellabio International Research Services Site Number : 8401411
    Pembroke Pines, Florida 33025, United States
  • Clinical Research of West Florida - Tampa - North Howard Avenue- Site Number : 8402008
    Tampa, Florida 33606, United States
  • Appalachian Clinical Research Site Number : 8400024
    Calhoun, Georgia 30701, United States
  • Private Practice - Dr. David Kavtaradze- Site Number : 8401029
    Cordele, Georgia 31015, United States
  • Alpha Clinical Research Group - Dunwoody- Site Number : 8401190
    Dunwoody, Georgia 30350, United States
  • Covenant Pulmonary Critical Care Site Number : 8401183
    East Point, Georgia 30344, United States
  • OSF Saint Fracis Medical Center- Site Number : 8402024
    Peoria, Illinois 61637, United States
  • Benchmark Research - Covington- Site Number : 8401193
    Covington, Louisiana 70433, United States
  • Care Access - Shreveport- Site Number : 8402047
    Shreveport, Louisiana 71105, United States
  • Private Practice - Dr. Paul Shapero- Site Number : 8401016
    Bangor, Maine 04401, United States
  • Care Access - Boston- Site Number : 8402276
    Boston, Massachusetts 02110, United States
  • Revive Research Institute - Lathrup Village- Site Number : 8402186
    Lathrup Village, Michigan 48076, United States
  • Pulmonary and Medicine Associates- Site Number : 8401403
    Warren, Michigan 48088, United States
  • Hannibal Regional Healthcare System-HRMG-Hannibal Site Number : 8401383
    Hannibal, Missouri 63401-6890, United States
  • Midwest Chest Consultants- Site Number : 8401002
    Saint Charles, Missouri 63301, United States
  • Washington University- Site Number : 8402035
    St Louis, Missouri 63110, United States
  • Henderson Clinical Trials Site Number : 8401365
    Henderson, Nevada 89052, United States
  • VA Western New York Healthcare System Site Number : 8402050
    Buffalo, New York 14215, United States
  • Schenectady Pulmonary and Critical Care Associates - Schenectady Main Office- Site Number : 8402029
    Schenectady, New York 12308, United States
  • East Carolina University- Site Number : 8401022
    Greenville, North Carolina 27858, United States
  • Advanced Respiratory and Sleep Medicine - Huntersville- Site Number : 8400022
    Huntersville, North Carolina 28078, United States
  • OK Clinical Research- Site Number : 8402001
    Edmond, Oklahoma 73034, United States
  • Clinical Research Associates of Central PA - Dubois- Site Number : 8401023
    DuBois, Pennsylvania 15801, United States
  • Allegheny General Hospital- Site Number : 8402058
    Pittsburgh, Pennsylvania 15212, United States
  • MedTrial- Site Number : 8402048
    Columbia, South Carolina 29204, United States
  • Clinical Research of Rock Hill Site Number : 8401008
    Rock Hill, South Carolina 29732, United States
  • REX Clinical Trials - Beaumont- Site Number : 8401371
    Beaumont, Texas 77701, United States
  • South Texas Medical Research Institute - TTS Research- Site Number : 8402012
    Boerne, Texas 78006, United States
  • ClinRx Research - Carrollton- Site Number : 8401021
    Carrollton, Texas 75007, United States
  • Corsicana Medical Research- Site Number : 8401018
    Corsicana, Texas 75110, United States
  • The Methodist Hospital Research Institute Site Number : 8401194
    Houston, Texas 77030, United States
  • Metroplex Pulmonary and Sleep Center Site Number : 8401015
    McKinney, Texas 75069, United States
  • Clear Lake Specialties Research Center, PLLC Site Number : 8401025
    Webster, Texas 77598, United States
  • Rheumatology & Pulmonary Clinic- Site Number : 8402053
    Beckley, West Virginia 25801, United States
  • Investigational Site Number : 0320012
    Berazategui, Buenos Aires 1886, Argentina
  • Investigational Site Number : 0320013
    La Plata, Buenos Aires B1900BNN, Argentina
  • Investigational Site Number : 0320003
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320007
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320008
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320011
    Rosario, Santa Fe Province 2000, Argentina
  • Investigational Site Number : 0320010
    Buenos Aires, 1023, Argentina
  • Investigational Site Number : 0320005
    Buenos Aires, 1414, Argentina
  • Investigational Site Number : 0320002
    Buenos Aires, 1425, Argentina
  • Investigational Site Number : 0320006
    Buenos Aires, 1638, Argentina
  • Investigational Site Number : 0320009
    Buenos Aires, 1650, Argentina
  • Investigational Site Number : 0320004
    Mendoza, 5500, Argentina
  • Centro de Diagnostico e Pesquisa da Osteoporose do Espirito Santo- Site Number : 0760009
    Vitória, Espírito Santo 29055-450, Brazil
  • Serviços Especializados em Reumatologia- Site Number : 0760020
    Salvador, Estado de Bahia 40150-150, Brazil
  • Centro De Cardiologia Clinica E Pesquisa- Site Number : 0760018
    Brasília, Federal District 70710-100, Brazil
  • Santa Casa de Misericordia de Belo Horizonte- Site Number : 0760014
    Belo Horizonte, Minas Gerais 30150-221, Brazil
  • Centro de Estudos em Terapias Inovadoras- Site Number : 0760012
    Curitiba, Paraná 80030-110, Brazil
  • Irmandade da Santa Casa de Misericórdia de Porto Alegre- Site Number : 0760001
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Instituto Ceos Site Number : 0760021
    Porto Alegre, Rio Grande do Sul 90480-020, Brazil
  • Hospital São Lucas da PUCRS - Porto Alegre - Avenida Ipiranga- Site Number : 0760007
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • WM Pesquisas Clínicas em Doenças Respiratórias- Site Number : 0760006
    Porto Alegre, Rio Grande do Sul 91010-006, Brazil
  • Universidade Estadual Paulista - Faculdade de Medicina de Botucatu- Site Number : 0760005
    Botucatu, São Paulo 18618-970, Brazil
  • Hospital e Maternidade Celso Pierro - PUC-Campinas- Site Number : 0760010
    Campinas, São Paulo 13034-685, Brazil
  • Centro Multidisciplinar de Estudos Clínicos- Site Number : 0760015
    São Bernardo do Campo, São Paulo 09715-090, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo- Site Number : 0760013
    São Paulo, 04014-002, Brazil
  • Investigational Site Number : 1000004
    Gabrovo, 5300, Bulgaria
  • Investigational Site Number : 1000007
    Haskovo, 6300, Bulgaria
  • Investigational Site Number : 1000018
    Rousse, 7000, Bulgaria
  • Investigational Site Number : 1000010
    Rousse, 7002, Bulgaria
  • Investigational Site Number : 1000016
    Sofia, 1142, Bulgaria
  • Investigational Site Number : 1000001
    Sofia, 1233, Bulgaria
  • Investigational Site Number : 1000009
    Sofia, 1756, Bulgaria
  • Investigational Site Number : 1000017
    Stara Zagora, 6000, Bulgaria
  • Investigational Site Number : 1000003
    Stara Zagora, 6003, Bulgaria
  • Investigational Site Number : 1000013
    Veliko Tarnovo, 5000, Bulgaria
  • Investigational Site Number : 1000006
    Vidin, 3700, Bulgaria

Showing the first 100 of 223 sites across 32 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Sep 2026, 31 months.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 31 months is above that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2024
First posted
Jan 17, 2024
StartActual
Jan 11, 2024
Primary completionActual
Sep 10, 2026
CompletionActual
Sep 10, 2026
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06208306
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Jan 17, 2024
Start date
Jan 11, 2024
Primary completion
Sep 10, 2026
Completion
Sep 10, 2026
Last update
Sep 18, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Itepekimab

Start the discussion